Pfizer's Next-Gen Pneumonia Vaccine Beats Prevnar 20; BMS Deploys Anthropic AI

Retatrutide just posted up to 30.3 percent weight loss in TRIUMPH-1 — Lilly's first pivotal Phase 3, with seven more readouts on deck this year.

And Merck's TROP2 ADC slashed progression risk by 65 percent over Keytruda alone in first-line lung cancer ahead of ASCO. Big data day — let's break it down.

Welcome to The Pharma Closeout for Thursday, May 21st, 2026. I'm Alex Mercer.

And I'm Maya Patel. Let's get into it.

Eli Lilly disclosed topline results from TRIUMPH-1 today, the first pivotal Phase 3 trial for retatrutide, their triple-acting GLP-1/GIP/glucagon receptor agonist. The headline: weight loss of up to an average of 71.2 pounds, translating to roughly 30.3 percent body weight reduction. The trial also hit a co-primary endpoint showing substantial relief from osteoarthritis pain. LLY shares closed up 2.24 percent.

The osteoarthritis co-primary is the real strategic play here. Linking weight loss directly to a specific comorbidity outcome isn't just clinical rigor — it's reimbursement architecture. If retatrutide gets labeled for OA pain improvement, payers can no longer frame this as a lifestyle intervention. You're arguing disease modification, and that's a fundamentally different coverage conversation.

We flagged this back in March — we said each retatrutide Phase 3 readout would either confirm or complicate the narrative. TRIUMPH-1 confirms it emphatically. The magnitude matters: tirzepatide delivered roughly 22.5 percent weight loss in SURMOUNT. Retatrutide at 30.3 percent represents a different tier of efficacy, even accounting for trial design and population differences.

Don't crown best-in-class on one readout, though. The glucagon component drives incremental fat oxidation and energy expenditure beyond what dual agonists achieve — but tolerability across the full TRIUMPH program matters just as much as peak weight loss. Hepatic and GI signals at the higher doses are what I'll be watching most closely in the remaining data.

And that's exactly why the rest of the year is so loaded. Lilly says seven additional Phase 3 readouts are expected in 2026 — different populations, different comorbidities, different dose ranges. Each one fills in a different piece of the risk-benefit map.

CagriSema already took a hit after REDEFINE underwhelmed — as we've covered. Novo is now staring down a 30 percent weight loss bar with nothing in-hand that comes close. The gap in next-generation obesity pharmacology just widened by a margin that pipeline programs alone may not close.

Lilly is stacking this on top of an already dominant position — Zepbound commercially established, Foundayo approved in April, and now retatrutide posting the strongest efficacy signal the class has seen. If even half the remaining readouts land cleanly, this stops being a pipeline story and starts looking like a commercial moat that competitors will spend years trying to scale.

Lilly wasn't the only company posting landmark data today. Shifting to the deal and pipeline side — the other headline belongs to Merck and their partner Kelun-Biotech. Their TROP2 ADC sacituzumab tirumotecan — sac-TMT — combined with Keytruda cut the risk of progression or death by 65 percent versus Keytruda monotherapy in first-line PD-L1-positive NSCLC. A positive trend in overall survival was also observed. Per Kelun's announcement, this is the first Phase 3 trial of an ADC combined with a checkpoint inhibitor to hit its primary endpoint in first-line NSCLC. Full data will feature in the official ASCO 2026 Press Program.

A 65 percent risk reduction on PFS implies a hazard ratio around 0.35 — that's not incremental, that's a fundamentally different treatment paradigm. But the detail oncologists will parse most carefully is the OS trend without mature data. In first-line NSCLC, PFS improvements that never translate to overall survival have burned sponsors before. The mature readout will determine whether this becomes practice-changing or joins a long list of impressive PFS signals that didn't hold up at the survival endpoint.

Merck is also presenting Keytruda plus Trodelvy in metastatic triple-negative breast cancer at ASCO — the ASCENT-04 data. The ADC combination playbook is being stress-tested across multiple tumor types at once, and that's by design. Merck's entire post-LOE franchise depends on proving Keytruda-based combinations extend its dominance beyond monotherapy. MRK shares up 2.55 percent on the session.

BioMarin reported positive Phase 3 pivotal results for Voxzogo in children with hypochondroplasia — the CANOPY-HCH-3 study. Annualized growth velocity improved by a least-squares mean difference of 2.33 centimeters per year over placebo, p-value below 0.0001. That positions a label expansion for their top-selling drug well beyond achondroplasia into broader forms of short stature — a genuine TAM multiplier for a franchise already carrying the company.

Quick hits. Zentalis surged about 12 percent on Phase 1b MUIR data for azenosertib plus paclitaxel in platinum-resistant ovarian cancer — early-stage, but the WEE1 inhibitor class is drawing serious interest. Separately, Incyte expanded its AI drug discovery collaboration with Genesis Molecular to a 120 million dollar upfront package and inked a new partnership with Edison Scientific. Both deals are structured around training AI platforms on Incyte's proprietary experimental data — a model where historical clinical data becomes the strategic asset.

And Biogen and Denali put out a Phase 2b update on BIIB122 from the LUMA study in Parkinson's disease. Specific numerical endpoints haven't surfaced yet. We flagged Denali back in March, and LRRK2 inhibition remains the highest-profile disease-modifying bet in neurodegeneration. Even a modestly positive signal here repositions both companies overnight and changes the investment thesis for every Parkinson's competitor behind them.

Also worth noting on the regulatory front — a calendar correction to flag. We've been tracking the Leqembi subcutaneous autoinjector PDUFA, which was originally set for May 24th. Per an Eisai release dated May 8th, that date has been pushed to August 24th, 2026. If you had this circled for the weekend, recalibrate.

A three-month delay. Subcutaneous Leqembi is the convenience play Eisai needs for broader commercial adoption — it's the difference between infusion-center visits and at-home dosing. The delay doesn't kill the thesis, but it hands time back to competitors in the Alzheimer's space and slows the volume ramp Eisai is counting on.

On the leadership front, Endpoints is reporting on an inside campaign to push out FDA Commissioner Marty Makary. That follows the Jeanne Hoeg firing and a growing list of senior vacancies we've been tracking for weeks. Layer on the Supreme Court rejecting pharma's challenge to Medicare drug price negotiations last Sunday — AstraZeneca, BMS, Janssen, Novartis, and Novo Nordisk all lost. And the Trump drug pricing executive order threatening cuts of up to 80 percent continues to hang over the entire sector. The regulatory and pricing pressure is compounding, not stabilizing.

A couple more items in brief. Tavneos patient starts have resumed in Japan despite the 20 reported deaths we covered previously — the market will parse whether resumption signals regulatory confidence or simply commercial necessity. And the FDA yesterday approved a gene therapy for genetic hearing loss, which the agency described as the first of its kind. Even amid internal turmoil, the review machinery continues to produce.

For now. Every week of leadership instability compounds uncertainty for sponsors sitting on pending applications. Institutional momentum covers the gaps for a while — not indefinitely. Sooner or later, the vacancies show up in review timelines, and the conversation shifts from who's running the FDA to whether the FDA can actually run.

Looking ahead to what to watch. ASCO 2026 owns the near-term calendar. The sac-TMT and Keytruda-Trodelvy data both hit the official Press Program, and a wave of oncology abstracts from Legend Biotech, Black Diamond, Agenus, Compass Therapeutics, and others are queued. Drug manufacturers broadly posted a strong session today — up 1.69 percent as a group, now up over 13 percent year-to-date. Expect the ADC-IO narrative to dominate oncology conversations for the next two weeks.

On the obesity side, TRIUMPH-1 was the opening chapter. If the next couple of Lilly's seven remaining Phase 3 readouts confirm this magnitude, the reset in obesity pharmacology becomes irreversible — and Novo's strategic response will define their trajectory for the rest of the decade.

And keep watching for the full LUMA dataset from Biogen and Denali. A genuine disease-modification signal in Parkinson's would be the most consequential neuroscience readout of the year — and it would reframe the risk calculus for every company still debating whether neurodegeneration assets are worth the Phase 3 investment.

That is your Pharma Closeout for Thursday. Retatrutide rewriting the obesity playbook at 30 percent weight loss, Merck and Kelun cracking the ADC-IO code in lung cancer, BioMarin pushing Voxzogo into new territory, and the FDA leadership questions far from settled. If this briefing saves you time, follow us on Spotify and drop a rating — it helps other pharma professionals find the show. We are back tomorrow.

Enjoy your Thursday evening, everyone. We'll see you tomorrow.